Side-by-side · Research reference

CrystagenvsHGH 191AA

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-MechanisticHUMAN-REVIEWED12/40 cited

BFDA-ApprovedHUMAN-REVIEWED0/75 cited

Crystagen

Khavinson Bioregulator · Immune-Thymic

B-cellPrimary targetСhervyakova 2014

SpleenTissue specificityСhervyakova 2014

AnimalEvidence level

SQ · Protocol variable

HGH 191AA

Recombinant hGH · FDA-Approved

0.024–0.034 mg/kg/dayPediatric GHD dose

2–4 hoursPlasma half-life

191 AASequence length

SQ · Daily · Evening preferred

01Mechanism of Action

Parameter

Crystagen

HGH 191AA

Primary target

B-lymphocytes in splenic tissueСhervyakova 2014

Growth hormone receptor (GHR) — JAK2/STAT5 pathway

Pathway

B-cell activation → Immune modulation during agingСhervyakova 2014

GHR activation → JAK2/STAT5 → liver IGF-1 synthesis + direct metabolic effects

Downstream effect

B-cell activation via apoptosis reduction; no observed increase in splenic cell renewalСhervyakova 2014

Linear growth, lipolysis, protein synthesis, nitrogen retention, carbohydrate metabolism modulation

Feedback intact?

Unknown — bioregulator mechanism not fully characterized

No — exogenous GH bypasses hypothalamic-pituitary axis, suppresses endogenous pulsatility

Origin

Synthetic Lys-Glu-Asp-Gly tetrapeptide — Khavinson bioregulator series

Recombinant DNA technology — 191 AA, identical to pituitary hGH, no methionyl residue

Antibody development

—

Rare — <2% develop binding antibodies, typically non-neutralizing

02Dosage Protocols

Parameter

Crystagen

HGH 191AA

Standard dose

Not standardized — variable protocols

Russian bioregulator literature does not specify unified human dosing.

—

Evidence basis

Animal / mechanistic

FDA-approved / decades of RCT data

Route

Subcutaneous (presumed from bioregulator class)

—

Frequency

Unknown — bioregulator protocols variable

Once daily, typically evening

Evening administration mimics physiological GH pulse.

Duration

Unknown — chronic administration presumed in animal models

Years (children until epiphyseal closure); indefinite (adult GHD)

Half-life

Not reported

—

Pediatric GHD

—

0.024–0.034 mg/kg/day SQ

6–7× per week dosing typical. Brand-specific ranges.

Adult GHD

—

0.004–0.016 mg/kg/day SQ

Start low, titrate based on IGF-1 levels.

Turner syndrome

—

0.045–0.050 mg/kg/day SQ

Idiopathic short stature

—

0.037 mg/kg/day SQ

AIDS wasting

—

0.1 mg/kg/day SQ (high-dose)

Short-term indication. Monitor glucose.

Monitoring

—

IGF-1, glucose, thyroid function, bone age (children)

03Metabolic / Fat Loss Evidence

Parameter

Crystagen

HGH 191AA

Primary fat target

—

Visceral and subcutaneous adipose tissue

Mechanism

—

Lipolysis via hormone-sensitive lipase activation, FFA oxidation

Effect on lean mass

—

Significant lean mass increase (protein synthesis, nitrogen retention)

Insulin sensitivity

—

Acute insulin resistance (anti-insulin effect); chronic neutral-to-improved via fat loss

IGF-1 elevation

—

Dose-dependent, significant — primary anabolic mediator

Glucose metabolism

—

Hyperglycemia risk, especially high doses (AIDS wasting)

Body composition

—

↓ fat mass, ↑ lean mass, ↑ bone mineral density (children)

Clinical context

—

FDA-approved for AIDS wasting (cachexia). Off-label use for body recomposition lacks long-term safety data.

04Side Effects & Safety

Parameter

Crystagen

HGH 191AA

Published adverse events

None reported in available animal literature

—

Human safety data

Absent — no controlled human trials identified

—

Autoimmune considerations

Theoretical concern with B-cell modulators in predisposed individuals

—

Injection site reaction

—

Lipohypertrophy, lipoatrophy, erythema (rotate sites)

Fluid retention / Edema

—

Peripheral edema, arthralgia, carpal tunnel syndrome (dose-dependent)

Glucose intolerance

—

Hyperglycemia, new-onset diabetes (anti-insulin effect)

Intracranial hypertension

—

Benign intracranial hypertension (pseudotumor cerebri) — headache, visual changes, papilledema

Slipped capital femoral epiphysis

—

SCFE risk in children — limp, hip/knee pain (requires surgery)

Scoliosis progression

—

Rapid growth may unmask/progress scoliosis (monitor spine in children)

Hypothyroidism

—

Central hypothyroidism unmasking or worsening (monitor TSH, free T4)

Cancer risk

—

Contraindicated in active malignancy. Theoretical risk in cancer survivors (controversial).

Antibody formation

—

Rare (<2%), typically non-neutralizing. Loss of efficacy if neutralizing antibodies develop.

Pancreatitis

—

Rare. Higher risk in children with certain syndromes (Prader-Willi).

Gynecomastia

—

Adolescent males (physiological during puberty, may be exacerbated)

Absolute Contraindications

Crystagen

·Active autoimmune disease (theoretical)

HGH 191AA

·Active malignancy or history of cancer (especially childhood cancer survivors with risk factors)
·Acute critical illness (post-cardiac surgery, trauma, acute respiratory failure)
·Diabetic retinopathy (active proliferative or severe non-proliferative)
·Prader-Willi syndrome with severe obesity, sleep apnea, or respiratory impairment
·Closed epiphyses (for growth indications)

Relative Contraindications

Crystagen

·Pregnancy / lactation (no data)
·Active B-cell malignancies

HGH 191AA

·Diabetes mellitus (monitor closely, may require insulin adjustment)
·Intracranial lesions or history of intracranial hypertension
·Scoliosis (monitor curve progression)
·Untreated hypothyroidism (treat before GH initiation)
·Severe obesity (assess OSA risk, cardiovascular status)

05Administration Protocol

Parameter

Crystagen

HGH 191AA

1. Route

Subcutaneous injection — presumed from bioregulator class convention. Specific anatomical sites not standardized.

Add diluent (sterile water or bacteriostatic water per manufacturer) to vial. Swirl gently — do not shake. Solution should be clear, colorless. Concentration varies by brand (e.g., 5 mg or 10 mg per vial).

2. Reconstitution

Protocol not standardized. If lyophilized, sterile water or bacteriostatic saline typical for peptide bioregulators.

Subcutaneous — rotate sites: abdomen, thigh, buttocks, upper arm. Avoid same site within 1 cm for 2 weeks to prevent lipodystrophy.

3. Timing

Not specified. Bioregulator protocols vary — some practitioners advocate evening dosing, others morning.

Once daily, evening preferred (6–8 PM or pre-sleep). Mimics physiological nocturnal GH secretion. Consistency is critical.

4. Storage

Lyophilized: room temperature, light-protected. Reconstituted: refrigerate, use within days to weeks depending on preservative.

Unreconstituted: refrigerate 2–8 °C, protect from light. Reconstituted: refrigerate, use within 14–28 days (brand-specific). Do not freeze.

5. Needle

—

27–31G, 4–8 mm insulin syringe or pen device. Pinch skin, 45–90° angle depending on subcutaneous thickness.

6. Monitoring

—

Baseline and periodic: IGF-1 (target age/sex-adjusted midrange), fasting glucose, HbA1c, thyroid function (TSH, free T4), bone age (children), lipid panel. Fundoscopy if headache/visual symptoms.

06Stack Synergy

Crystagen

+ Vilon

Multi-pathway

View Vilon →

Vilon (Lys-Glu) activates T-helper cells via apoptosis reduction, while Crystagen activates B-cells. Dual T/B immune modulation in aging models may provide complementary thymic-immune support within the Khavinson bioregulator framework. Both target splenic immune aging through distinct lymphocyte subsets.

Crystagen: Dose unknown · SQ
Vilon: Dose unknown · SQ
Frequency: Protocol variable
Primary benefit: Broader thymic-immune coverage (T-cell + B-cell)

Сhervyakova 2014

HGH 191AA

+ Ipamorelin

Moderate

View Ipamorelin →

Ipamorelin (GHRP) stimulates endogenous GH release, which is redundant when exogenous rhGH is administered. However, ipamorelin may still amplify pulsatility of remaining endogenous secretion in partial GHD or during GH dose titration. Not typically combined in standard clinical practice; more common in experimental or off-label protocols. Limited evidence for additive benefit.

HGH 191AA: Standard dose per indication
Ipamorelin: 100–200 mcg SQ · morning (if used)
Note: Monitor IGF-1 closely; avoid supraphysiological levels
Primary benefit: Theoretical enhancement of pulsatility; limited clinical rationale

+ Tesamorelin

Weak

View Tesamorelin →

Tesamorelin (GHRH analogue) stimulates endogenous GH secretion, which is unnecessary when exogenous rhGH is already provided. Combining both offers no mechanistic advantage and increases cost, side effects, and IGF-1 elevation risk. Not recommended in clinical practice.

Note: Combination not recommended — choose one GH modality
Primary benefit: None — redundant mechanisms